Nanobiotix (NASDAQ:NBTX) Upgraded at UBS Group

UBS Group upgraded shares of Nanobiotix (NASDAQ:NBTX) to a hold rating in a research note published on Monday morning,Zacks.com reports.

Nanobiotix Price Performance

Shares of Nanobiotix stock opened at $3.60 on Monday. Nanobiotix has a 52 week low of $2.76 and a 52 week high of $7.51. The business has a 50 day moving average price of $3.30 and a 200-day moving average price of $4.15.

Institutional Trading of Nanobiotix

Institutional investors and hedge funds have recently modified their holdings of the stock. OLD Mission Capital LLC purchased a new stake in shares of Nanobiotix during the fourth quarter valued at approximately $139,000. Jane Street Group LLC purchased a new stake in shares of Nanobiotix during the fourth quarter valued at approximately $73,000. Millennium Management LLC purchased a new stake in shares of Nanobiotix during the fourth quarter valued at approximately $39,000. Finally, Geode Capital Management LLC purchased a new stake in shares of Nanobiotix during the fourth quarter valued at approximately $29,000. 38.81% of the stock is owned by hedge funds and other institutional investors.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.